In This Article:
Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).
The University of Calgary Cumming School of Medicine's clinical team has begun screening trial subjects and dosed the first subject in Calgary, Alberta.
The multicentre, international, randomised, double-blind, placebo-controlled trial will evaluate the drug candidate versus placebo.
It aims to recruit 240 participants, with 120 patients each to be randomised into the LSALT peptide or placebo arms.
The trial’s primary goal is to assess the percentage of patients with acute kidney injury within seven days of on-pump cardiac surgery, in line with the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.
Participants will be monitored for safety and efficacy until day 28, with day one regarded as the day of subject randomisation and the study drug administration at least one hour before the induction of anaesthaesia.
An independent Data and Safety Monitoring Board (DSMB) will evaluate patient data, focusing primarily on safety assessments.
LSALT peptide works by targeting the dipeptidase-1 (DPEP1) pathway. Its potential in preventing ischaemia-reperfusion injury to the kidneys was demonstrated in pre-clinical models.
Arch Biopartners CEO Richard Muruve said: “We are happy to see the team at the University of Calgary Hospital recruit and dose the first patient in Canada for our Phase II study targeting CS-AKI.
“Our five clinical sites in Turkey have made good recruitment progress and have done a great job executing the trial to date.
“The start of recruitment in Calgary, followed by the activation into the study of the two Toronto hospitals, will significantly boost the momentum of the trial.”
In addition to Canada, Arch Biopartners has also begun recruiting and dosing subjects in Turkey for the Phase II trial of LSALT peptide.
"Arch Biopartners doses first subject in trial of acute kidney injury treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.